Cu-64 DOTATATE

PreclinicalSmall molecule

RRigshospitalet, Denmark

Cu-64 DOTATATE is one of 12 small molecule programs targeting Cardiac Sarcoidosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac SarcoidosisActive, not recruiting

Cardiac SarcoidosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Cardiac Sarcoidosis

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Approved

1 2

Trexall

Alnylam Pharmaceuticals

Phase 3

1 3

Olumiant

Eli Lilly

Phase 2

1 4

Prednisone or Prednisolone

Johnson & Johnson

Phase 3

1 5

Kineret

SSwedish Orphan Biovitrum

Phase 2

1 6

Arcalyst

KKiniksa Pharmaceuticals (UK), Ltd.

Phase 2

1 7

Namilumab

Takeda

Phase 2

1 8

Tc-99m Tilmanocept

NNavidea Biopharmaceuticals

Phase 2

1 9

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Inpefa

LLexicon Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiac Sarcoidosis1 trial

Somatostatin Receptor Imaging in Cardiac Sarcoidosis

Withdrawn·RRigshospitalet, Denmark··NCT02812849

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cu-64 DOTATATE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cu-64 DOTATATE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cu-64 DOTATATE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rigshospitalet, Denmark company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRigshospitalet, Denmark

Cu-64 DOTATATE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiac Sarcoidosis1 trial

References

Drug Info

Quick Facts

Related News